177 related articles for article (PubMed ID: 15651132)
1. Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status.
Technol Eval Cent Assess Program Exec Summ; 2004 Dec; 19(9):1-2. PubMed ID: 15651132
[No Abstract] [Full Text] [Related]
2. Antipsychotic medications and ethnicity.
Berg MJ
J Gend Specif Med; 1998; 1(2):16-7. PubMed ID: 11281006
[No Abstract] [Full Text] [Related]
3. Cytochrome P450 pharmacogenetics in African populations: implications for public health.
Dandara C; Swart M; Mpeta B; Wonkam A; Masimirembwa C
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):769-85. PubMed ID: 24588448
[TBL] [Abstract][Full Text] [Related]
4. Medical practice, race, and drug use.
Kalow W
Clin Pharmacol Ther; 2003 Jan; 73(1):132-4. PubMed ID: 12545152
[No Abstract] [Full Text] [Related]
5. Radical differences in CYP1A1 genotype and function.
Taioli E; Crofts F; Trachman J; Bayo S; Toniolo P; Garte SJ
Toxicol Lett; 1995 May; 77(1-3):357-62. PubMed ID: 7618162
[TBL] [Abstract][Full Text] [Related]
6. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.
Ball SE; Scatina J; Kao J; Ferron GM; Fruncillo R; Mayer P; Weinryb I; Guida M; Hopkins PJ; Warner N; Hall J
Clin Pharmacol Ther; 1999 Sep; 66(3):288-94. PubMed ID: 10511065
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
Kerb R; Fux R; Mörike K; Kremsner PG; Gil JP; Gleiter CH; Schwab M
Lancet Infect Dis; 2009 Dec; 9(12):760-74. PubMed ID: 19926036
[TBL] [Abstract][Full Text] [Related]
8. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.
MacPhee IA; Holt DW
Transplantation; 2008 Jan; 85(2):163-5. PubMed ID: 18212618
[TBL] [Abstract][Full Text] [Related]
9. Frequency of the frame-shifting CYP2D7 138delT polymorphism in a large, ethnically diverse sample population.
Bhathena A; Mueller T; Grimm DR; Idler K; Tsurutani A; Spear BB; Katz DA
Drug Metab Dispos; 2007 Aug; 35(8):1251-3. PubMed ID: 17494644
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
11. [Ethnicity in pharmacogenetics].
Sontoredjo TA; de Boer A; Maitland-van der Zee AH
Ned Tijdschr Geneeskd; 2013; 157(17):A6118. PubMed ID: 23614867
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and ethnoracial differences in smoking.
Sellers EM
JAMA; 1998 Jul; 280(2):179-80. PubMed ID: 9669793
[No Abstract] [Full Text] [Related]
13. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.
Liang R; Wang C; Zhao H; Huang J; Hu D; Sun Y
Thromb Res; 2012 Jul; 130(1):38-44. PubMed ID: 22192158
[TBL] [Abstract][Full Text] [Related]
14. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
[TBL] [Abstract][Full Text] [Related]
15. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.
Makeeva O; Stepanov V; Puzyrev V; Goldstein DB; Grossman I
Pharmacogenomics; 2008 Jul; 9(7):847-68. PubMed ID: 18597650
[TBL] [Abstract][Full Text] [Related]
16. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
[TBL] [Abstract][Full Text] [Related]
17. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J; Fayet A; Arab-Alameddine M; Rotger M; Lubomirov R; Cavassini M; Furrer H; Günthard HF; Colombo S; Csajka C; Eap CB; Decosterd LA; Telenti A;
Pharmacogenet Genomics; 2009 Apr; 19(4):300-9. PubMed ID: 19238117
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement.
Macphee IA; Fredericks S; Tai T; Syrris P; Carter ND; Johnston A; Goldberg L; Holt DW
Transplantation; 2002 Dec; 74(11):1486-9. PubMed ID: 12490779
[TBL] [Abstract][Full Text] [Related]
19. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the VNTR locus D1S80 in a Japanese population.
Nagai A; Yamada S; Bunai Y; Ohya I
Int J Legal Med; 1994; 106(5):268-70. PubMed ID: 8068572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
